Monlumax 200Mg - Anti-COVID Generic Drug Molnupiravir

Monlumax 200Mg - Anti-COVID Generic Drug Molnupiravir

Enquiry Now


Description

Monlumax 200Mg - Anti-COVID Generic Drug Molnupiravir


ACME  branded generic version of Molnupiravir will be marketed by Monlumax 200 (Molnupiravir 200 mg INN) Developed by the US based pharma Merck & Ridgeback


Additional Information


Molnupiravir is the world’s first oral pill to treat symptomatic COVID-19 which was approved by the UK’s Medicines and Healthcare products Regulatory Agency on 4 November 2021. Molnupiravir is originally developed by the US based pharma major Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics.


You May Also Like...

TESTIMONIALS